Johnson & Johnson (NYSE:JNJ) had its price objective raised by Raymond James from $145.00 to $147.00 in a research report sent to investors on Wednesday, BenzingaRatingsTable reports. They currently have an outperform rating on the stock.
A number of other equities research analysts also recently weighed in on JNJ. Zacks Investment Research downgraded Johnson & Johnson from a buy rating to a sell rating in a report on Tuesday, December 18th. Morgan Stanley set a $140.00 price objective on Johnson & Johnson and gave the company a hold rating in a research note on Thursday, December 20th. Citigroup reduced their price objective on Johnson & Johnson from $148.00 to $139.00 and set a neutral rating for the company in a research note on Wednesday, January 2nd. Wells Fargo & Co reissued an outperform rating and issued a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Finally, Barclays reissued an equal weight rating and issued a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $146.40.
Shares of JNJ stock opened at $137.52 on Wednesday. The company has a market capitalization of $368.95 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 2.38 and a beta of 0.68. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The firm’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the company posted $2.06 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in JNJ. Evolution Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $40,000. Crewe Advisors LLC boosted its position in shares of Johnson & Johnson by 75.0% during the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock valued at $45,000 after buying an additional 150 shares during the last quarter. Horan Securities Inc. boosted its position in Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after purchasing an additional 241 shares during the last quarter. First Bank & Trust boosted its position in Johnson & Johnson by 30.4% in the first quarter. First Bank & Trust now owns 399 shares of the company’s stock worth $56,000 after purchasing an additional 93 shares during the last quarter. Finally, Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the first quarter worth $58,000. 67.32% of the stock is owned by hedge funds and other institutional investors.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.